FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891468114> ?p ?o ?g. }

• W2891468114 abstract "e18548 Background: Generic imatinib therapy is being globally considered due to cost considerations. Evidence about its efficacy and safety in developing country settings, however, is scarce. Methods: The efficacy and safety of generic imatinib among Jordanian patients diagnosed with chronic myeloid leukemia (CML) was assessed utilizing an observational, multicenter, prospective study design. All patients (N = 91) were adults with CML treated with generic imatinib, mainly 400 mg/day, who either received generic imatinib (n = 33) as first-line therapy “first-line patients “or switched from patented imatinib to generic imatinib “switched patients” (n = 58). The primary objective was to measure proportions (95% Confidence Interval (CI)) of optimal response for first-line and switched patients at 12 months of treatment with generic imatinib, as defined in the 2009 ELN guidelines (CCyR [no Ph+ metaphases], or MMR [a ratio of BCR-ABL1 to ABL1 ≤0.1% on the International Scale]) and assessed by complete blood counts, fluorescence in situ hybridization and real-time quantitative PCR. Results: A total of 84.8% (n = 28/33) of the first-line patients achieved complete hematologic response (CHR) within 3 months of starting generic imatinib therapy (100% after 6 months). Out of the 23 evaluable first-line patients, [(87%, 95% CI = 73% - 100%), (n = 20)] in the per-protocol population (60.6 %, 95% CI = 51% - 86%) of the 33 patients in the intention-to-treat (ITT) population) achieved an optimal response at 12 months. All 58 switched patients had CHR at enrollment. Out of the 55 evaluable switched patients, [(96.4%, 95% CI = 91%-100%), (n = 53)] in the PP population (91.4%, 95% CI = 83%-98%) of the 58 patients in the ITT population) gained or maintained an optimal response at 12 months after switching to generic imatinib therapy. Most (84.7%, n = 144 out of 170) adverse events (AEs) were mild. Frequencies of drug-related AEs were similar to patented imatinib. Conclusions: Efficacy and safety of generic imatinib among middle eastern population in routine clinical practice is comparable to that of patented imatinib, and to that of the global population. Clinical trial information: NCT02977312." @default.
• W2891468114 created "2018-09-27" @default.
• W2891468114 creator A5005031809 @default.
• W2891468114 creator A5024262718 @default.
• W2891468114 creator A5031350381 @default.
• W2891468114 creator A5088492591 @default.
• W2891468114 date "2017-05-20" @default.
• W2891468114 modified "2023-09-27" @default.
• W2891468114 title "Generic imatinib therapy among Jordanians: An observational assessment of safety and efficacy in routine clinical practice." @default.
• W2891468114 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18548" @default.
• W2891468114 hasPublicationYear "2017" @default.
• W2891468114 type Work @default.
• W2891468114 sameAs 2891468114 @default.
• W2891468114 citedByCount "0" @default.
• W2891468114 crossrefType "journal-article" @default.
• W2891468114 hasAuthorship W2891468114A5005031809 @default.
• W2891468114 hasAuthorship W2891468114A5024262718 @default.
• W2891468114 hasAuthorship W2891468114A5031350381 @default.
• W2891468114 hasAuthorship W2891468114A5088492591 @default.
• W2891468114 hasConcept C126322002 @default.
• W2891468114 hasConcept C143998085 @default.
• W2891468114 hasConcept C16930146 @default.
• W2891468114 hasConcept C177713679 @default.
• W2891468114 hasConcept C23131810 @default.
• W2891468114 hasConcept C2775922572 @default.
• W2891468114 hasConcept C2777583451 @default.
• W2891468114 hasConcept C2778729363 @default.
• W2891468114 hasConcept C2779974597 @default.
• W2891468114 hasConcept C512399662 @default.
• W2891468114 hasConcept C71924100 @default.
• W2891468114 hasConceptScore W2891468114C126322002 @default.
• W2891468114 hasConceptScore W2891468114C143998085 @default.
• W2891468114 hasConceptScore W2891468114C16930146 @default.
• W2891468114 hasConceptScore W2891468114C177713679 @default.
• W2891468114 hasConceptScore W2891468114C23131810 @default.
• W2891468114 hasConceptScore W2891468114C2775922572 @default.
• W2891468114 hasConceptScore W2891468114C2777583451 @default.
• W2891468114 hasConceptScore W2891468114C2778729363 @default.
• W2891468114 hasConceptScore W2891468114C2779974597 @default.
• W2891468114 hasConceptScore W2891468114C512399662 @default.
• W2891468114 hasConceptScore W2891468114C71924100 @default.
• W2891468114 hasLocation W28914681141 @default.
• W2891468114 hasOpenAccess W2891468114 @default.
• W2891468114 hasPrimaryLocation W28914681141 @default.
• W2891468114 hasRelatedWork W132178418 @default.
• W2891468114 hasRelatedWork W1530487900 @default.
• W2891468114 hasRelatedWork W2040088531 @default.
• W2891468114 hasRelatedWork W2069423961 @default.
• W2891468114 hasRelatedWork W2079277436 @default.
• W2891468114 hasRelatedWork W2137053633 @default.
• W2891468114 hasRelatedWork W2137991831 @default.
• W2891468114 hasRelatedWork W2139910132 @default.
• W2891468114 hasRelatedWork W2156363246 @default.
• W2891468114 hasRelatedWork W2412544904 @default.
• W2891468114 hasRelatedWork W2416027285 @default.
• W2891468114 hasRelatedWork W2520687465 @default.
• W2891468114 hasRelatedWork W2555390992 @default.
• W2891468114 hasRelatedWork W2565631299 @default.
• W2891468114 hasRelatedWork W2570047924 @default.
• W2891468114 hasRelatedWork W2579361561 @default.
• W2891468114 hasRelatedWork W2803660120 @default.
• W2891468114 hasRelatedWork W2806669859 @default.
• W2891468114 hasRelatedWork W2944647869 @default.
• W2891468114 hasRelatedWork W2413586491 @default.
• W2891468114 isParatext "false" @default.
• W2891468114 isRetracted "false" @default.
• W2891468114 magId "2891468114" @default.
• W2891468114 workType "article" @default.